MedTrace Logo

Periarticular Multimodal Drug Injections in Total Knee Arthroplasty

NCT00901628 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2013-01-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether periarticular multimodal drug injection (PMDI) would provide additional benefits in patients after total knee arthroplasty (TKA) for whom contemporary pain control protocols using the continuous femoral nerve block, intra-venous patient controlled analgesia (IV-PCA)and preemptive oral medications. We hypothesized that PMDI would reduce pain level and consumption of PCA and acute pain rescuer and would provide better functional recovery and patient satisfaction. We also hypothesized that the incidence of side effects and complications of the PMDI would be similar to the No-PMDI.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

ropivacaine

300mg (0.75%, 40cc) intraoperative periarticular injection

DRUG

morphine sulfate

10mg intraoperative periarticular injection

DRUG

ketorolac

30 mg intraoperative periarticular injection

DRUG

epinephrine

300 microgram (1:1000) intraoperative periarticular injection

DRUG

cefuroxime

750mg intraoperative periarticular injection

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Tae Kyun Kim, MD, PhD · Joint Recontruction Center, Seoul National University Bundang hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00901628 on ClinicalTrials.gov